

Our ref: FOI ID 33174

30 January 2017

southseftonccg.foi@nhs.net

NHS South Sefton CCG

Merton House

Stanley Road

Bootle

Merseyside

L20 3DL

Tel: 0151 247 7000

Re: Freedom of Information Request

Please find below the response to your recent Freedom of Information request regarding the usage of Infliximab within NHS South Sefton CCG.

Request/[Response](#):

1. In the period of financial year to date:

- How many individual funding requests for the usage of Infliximab in the treatment of Hidradentis Suppurativa has the CCG received?

[NHS South Sefton CCG have received no funding requests for the usage of Infliximab.](#)

- Of the above, is it possible to say how many have been approved?

[Not applicable](#)

2. Are there any gainshare agreements in place between the CCG and a provider (e.g. hospital trust)?

If "Yes", then please provide the following details:

Disease area	Provider included in the gainshare agreement	Names of any specific drugs involved	What savings have been made (approximate amount)?

Chair: Dr Andrew Mimmagh
Chief Officer: Fiona Taylor



South Sefton
Clinical Commissioning Group

- Yes there are gain-share agreements in place between NHS South Sefton CCG and the large acute providers, Aintree University Hospitals NHS Foundation Trust, Southport & Ormskirk Hospital NHS Trust and The Royal Liverpool and Broadgreen University Hospitals NHS Trust
- The gain-share agreements cover the transfer of patients over to biosimilar drugs, various disease areas and various drugs
- Gain share is only rolling out this year and savings are not yet quantifiable

3. Have any gainshare agreements been terminated, and if so which disease areas?

NHS South Sefton CCG are not aware of any gainshare agreements which have been terminated.